The study reviews/comments on the associations of lifetime psilocybin (alone, no other drugs) use with past month psychological distress, past year suicidal thinking, past year suicidal planning, and past year suicide attempt in the US adult population. It found that “lifetime use of psilocybin but no other classic psychedelic may be especially protective with regard to psychological distress and suicidality.”
Abstract of Psilocybin, psychological distress, and suicidality
“Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = .81 (.72–.91)), past year suicidal thinking (weighted OR = .86 (.78–.94)), past year suicidal planning (weighted OR = .71 (.54–.94)), and past year suicide attempt (weighted OR = .64 (.46–.89)) in the United States adult population. Although these findings comport with an emerging literature suggesting classic psychedelics may be effective in the treatment of mental health conditions and prevention of self-harm, they do not speak to the potential risk profile or therapeutic applications of psilocybin in particular, which is the most commonly examined classic psychedelic in contemporary clinical research. Considering that psilocybin may be a candidate for future approved medical use in the United States, the United Kingdom, and other nations (Bogenschutz et al., 2015; Grob et al., 2011; Johnson et al., 2014; see also Nutt et al., 2013), an analysis of the specific relationships of psilocybin use with psychological distress and suicidality may help inform decisions by the United States Food and Drug Administration and regulatory bodies of other nations. The objectives of the current research, therefore, were to extend the analysis of Hendricks et al. (2015) by evaluating the associations of lifetime psilocybin use, per se, with past month psychological distress, past year suicidal thinking, past year suicidal planning, and past year suicide attempt in the United States adult population.”
Authors: Peter S. Hendricks, Matthew W. Johnson & Roland R. Griffiths
Analysis
The study used the survey data from Hendricks et al. (2015).
Summary of Psilocybin, psychological distress, and suicidality
Hendricks et al. (2015) found that having ever used any classic psychedelic substance was associated with a significantly reduced likelihood of psychological distress, suicidal thinking, suicidal planning, and suicide attempt. Although the findings of Hendricks et al. (2015) suggest that classic psychedelics may be effective in the treatment of mental health conditions and prevention of self-harm, they do not speak to the potential risk profile or therapeutic applications of psilocybin in particular.
Methods and data analysis were similar to those of Hendricks et al. (2015). Four mutually exclusive groups of respondents were examined: Psilocybin Only, Psilocybin & Other Psychedelics, Non-Psilocybin Psychedelics Only, and No Psychedelics.
Multivariate logistic regression was used to examine the relationships between group membership and outcome variables in a sample of people who had used psilocybin and other psychedelics.
Find this paper
Psilocybin, psychological distress, and suicidality
https://doi.org/10.1177/0269881115598338
Open Access | Google Scholar | Backup | 🕊
Cite this paper (APA)
Hendricks, P. S., Johnson, M. W., & Griffiths, R. R. (2015). Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 29(9), 1041-1043.
Study details
Compounds studied
Psilocybin
Topics studied
Suicidality
Study characteristics
Commentary
Survey
Participants
7550
Humans
Authors
Authors associated with this publication with profiles on Blossom
Peter HendricksPeter Hendricks is a Professor in the Department of Health Behaviour at the University of Alabama. Hendricks's area of expertise lies in substance abuse treatment and prevention.